Hengrui Pharmaceuticals Co., Ltd. Made Hurun Global 500 List by Moving up 47 Places Compared to Last Year

From: Lianyungang Daily Updated: 2024-02-22 08:51

Hurun Research Institute recently released the 2023 Hurun Global 500 list, and Hengrui Pharmaceuticals ranked 366th, an increase of 47 places from last year. According to statistics, there are a total of 48 medical and health companies on this list, of which 3 are Chinese companies. Hengrui Pharmaceuticals Co., Ltd. is the only pharmaceutical company in Jiangsu to be listed. Zhou Mengling, Deputy Director of the Municipal Science and Technology Bureau, stated that Hengrui was a model of technological innovation for Lianyungang-based enterprises, and its position in the international community is increasingly improving, gradually becoming a typical example of “go global” strategies for China's pharmaceutical industry.

This year, the 2023 Hurun Global 500 listed non-state-owned enterprises in the Fortune Global 500 based on their market value or valuation. The market value of listed companies is calculated based on the closing price on October 31, 2023, while the valuation of unlisted companies is with reference to the listed companies in the same industry or estimation according to the latest round of financing. This is the fourth consecutive time that Hurun Research Institute has released the “Hurun Global 500 List”.

Build a research and development platform and strengthen the construction of the research and development system. As an innovative international pharmaceutical enterprise, Hengrui Pharmaceuticals Co., Ltd. adheres to the strategy of technological innovation. Since the first innovative drug was approved for listing in 2011, its cumulative R&D investment has exceeded 33 billion yuan, ranking among the top in the national pharmaceutical industry. At present, Hengrui Pharmaceuticals Co., Ltd. has established 14 research and development centers in places such as Lianyungang, Shanghai, the United States and Europe, with a global research and development team of more than 5000 people. It has also established a number of international leading new technology platforms, including protein hydrolysis targeted chimeras (PROTAC), molecular gels, antibody conjugated drugs (ADC), and dual/multi specific antibodies, focusing on innovative research and development in multiple fields such as anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases and neurological diseases. At present, Hengrui Pharmaceuticals has been approved to market 16 Class 1 innovative drugs and 4 self-developed Class 2 new drugs in China. In addition, more than 80 independent innovative products are under clinical development, and more than 270 clinical trials are being conducted both domestically and internationally. Its research and development achievements have remained at the forefront of the industry.

While deeply cultivating and developing in the domestic innovation field, Hengrui Pharmaceuticals Co., Ltd. is steadily promoting internationalization. In terms of international clinical trials of innovative drugs, Hengrui Pharmaceuticals is currently conducting nearly 20 international clinical trials of innovative drugs. Among them, the application for the first-line treatment indication of liver cancer with the combination of Camrelizumab and Apatinib (the "Double Ai" combination) has been accepted by the US FDA; Camrelizumab, Haiqubopa and etc. have been recognized as orphan drugs by the US FDA. In the respect of open-up and cooperation, through cooperation with the United States, Germany, South Korea and India, Hengrui Pharmaceuticals has achieved overseas authorizations for 10 innovative drugs, including Camrelizumab, Pyrotinib, HRS-1167 and etc. In 2023 alone, Hengrui Pharmaceuticals has achieved 5 authorized collaborations with a total transaction amount of over 4 billion US dollars. Among them, the authorized cooperation with the large multinational enterprise Merck reached a total transaction amount of 1.4 billion Euros, which also marks the first time that Hengrui Pharmaceuticals has achieved strategic cooperation with a large multinational enterprise worldwide.

Under the guidance of the dual-wheel drive development strategy of technological innovation and internationalization, Hengrui Pharmaceuticals has achieved good results in relevant domestic and international evaluations. Hengrui Pharmaceuticals has been selected for 5 consecutive years on the "Top 50 Global Pharmaceutical Companies" list by Pharmaceutical Executive in the United States; in the "Top 25 Global Pharmaceutical Enterprise R&D Pipeline Scale" list selected by the global pharmaceutical think-tank information platform Informa Pharma Intelligence, Hengrui Pharmaceuticals ranks 13th, setting a new high for Chinese pharmaceutical companies on this list; China Pharmaceutical Industry Information Center has released the "Best Industrial Enterprises in China's Pharmaceutical R&D Product Line" over the years, and Hengrui Pharmaceuticals has topped the list 11 times. The enterprise’s innovation and R&D capacities have also been recognized by the international academic community. In 2023, multiple heavyweight research results were presented in top global journals such as The Lancet, British Medical Journal, and Nature Medicine, as well as oral presentations at important international academic conferences such as the American Society of Clinical Oncology and the European Society of Oncology.